Breakthrough: New Molecule SU212 Targets Triple-Negative Breast Cancer

Описание: Triple-negative breast cancer treatment advances with SU212 molecule from OHSU researchers.
Discover the latest breakthrough in fighting aggressive triple-negative breast cancer (TNBC), which affects up to 15% of breast cancer cases and lacks effective therapies. In a groundbreaking study published in Cell Reports Medicine, scientists developed SU212, a promising molecule that inhibits the ENO1 enzyme overexpressed in cancer cells.
This video explores how SU212 binds to enolase 1, promoting its degradation and suppressing tumor growth and metastasis in humanized mouse models. Led by Dr. Sanjay V. Malhotra, the research highlights potential benefits for patients with metabolic conditions like diabetes, and applications to other cancers including glioma, pancreatic, and thyroid carcinoma.
Learn about the path to clinical trials, FDA approval challenges, and why this could revolutionize TNBC treatment. Stay updated on breast cancer research and innovative cancer therapies.
Key highlights:
SU212's mechanism against ENO1
Results from preclinical studies
Broader implications for oncology
Expert insights from OHSU Knight Cancer Institute